Welcome to our dedicated page for Urogen Pharma SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with pharmacology tables, FDA timelines, and patent cliffs can feel overwhelming—especially with UroGen Pharma’s focus on RTGel®-enabled, non-surgical bladder cancer treatments. Investors want to know which clinical milestones drive revenue potential, how cash burn affects runway, and when management files Form 4 insider trades ahead of trial read-outs. Stock Titan’s AI transforms these dense disclosures into plain language, so you can spot pivotal details in seconds instead of hours.
Inside UroGen Pharma’s SEC filings you’ll find:
- 10-K annual reports tracing R&D spend, regulatory risk, and patent life; our summaries flag the key sections—perfect for anyone searching “UroGen Pharma annual report 10-K simplified”.
- 10-Q quarterly earnings that update cash runway and trial costs; look for the phrase “UroGen Pharma quarterly earnings report 10-Q filing” to jump straight to AI-highlighted financial shifts.
- 8-K material events covering FDA correspondence or partnership deals; our engine answers real questions like “What drove yesterday’s URGN move?” with line-by-line explanations.
- Form 4 insider transactions delivered in real time—ideal for tracking “UroGen Pharma insider trading Form 4 transactions” before the market reacts.
- Proxy statements detailing executive compensation and governance, invaluable when researching “UroGen Pharma proxy statement executive compensation”.
Every document arrives moments after hitting EDGAR and is paired with an AI-powered summary, contextual risk analysis, and citation links for deeper review. Whether you’re monitoring “UroGen Pharma Form 4 insider transactions real-time”, comparing trial expenses across quarters, or simply seeking “understanding UroGen Pharma SEC documents with AI”, Stock Titan keeps critical data organized, searchable, and clear—so you can focus on decisions, not document hunting.
Form 144 filed for UroGen Pharma Ltd. (URGN) reports a planned insider disposition.
- Securities: 5,149 ordinary shares.
- Estimated value: $97,573.55.
- Broker: Oppenheimer & Co., NASDAQ execution targeted for 28 Jul 2025.
- Total shares outstanding: 46,107,451; proposed sale equals ~0.011% of float.
- Share origin: Restricted Stock Units granted 31 Jan 2024 (10,000 units).
- Prior activity: Same seller disposed of 5,162 shares for $38,043.94 on 9 Jun 2025.
The filer certifies no undisclosed adverse information under Rule 144. Given the modest volume relative to outstanding shares, the transaction is unlikely to have a material price impact but continues a pattern of insider selling that investors may monitor.
UroGen Pharma Ltd. (URGN) – Form 144 filing. An unidentified insider has notified the SEC of an intended open-market sale of 7,522 ordinary shares through Oppenheimer & Co. on or after 28 Jul 2025. Based on the filer’s estimate, the block is worth $142,541.90, implying an indicative price of roughly $18.95 per share. The shares represent 0.016% of the company’s 46.1 million shares outstanding, a small fraction of float but still a required disclosure under Rule 144.
The shares stem from 16,500 restricted stock units granted and vested on 31 Jan 2024. The filer reports no other URGN share sales in the prior three months. The filer also certifies that no undisclosed material adverse information is known. While modest in size, the transaction flags upcoming insider liquidity and may be watched as a sentiment signal.
FAQ
What is the current stock price of Urogen Pharma (URGN)?
What is the market cap of Urogen Pharma (URGN)?
